Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double‐Blind, Placebo‐Controlled REGAIN, and Pooled EVOLVE‐1 and EVOLVE‐2 StudiesTodd A. Smitherman, Eric Pearlman, Sarah Lipsius et al.|Headache The Journal of Head and Face Pain|2020Cited by 35
Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: <i>post hoc</i> analyses of three randomized double‐blind studiesJessica Ailani, Sheena K. Aurora, Eric Pearlman et al.|European Journal of Neurology|2019Cited by 26